EP1622564A2 - Diazabicyclononene derivatives - Google Patents
Diazabicyclononene derivativesInfo
- Publication number
- EP1622564A2 EP1622564A2 EP04729414A EP04729414A EP1622564A2 EP 1622564 A2 EP1622564 A2 EP 1622564A2 EP 04729414 A EP04729414 A EP 04729414A EP 04729414 A EP04729414 A EP 04729414A EP 1622564 A2 EP1622564 A2 EP 1622564A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- lower alkyl
- mixtures
- compounds
- diastereomers
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the invention relates to novel compounds of the general formula I.
- the invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula I and especially their use as renin inhibitors in cardiovascular events and renal insufficiency.
- these compounds can be regarded as inhibitors of other aspartyl proteases and might therefore be useful as inhibitors of plasmepsins to treat malaria and as inhibitors of Candida albicans secreted aspartyl proteases to treat fungal infections.
- renin inhibitors The rationale to develop renin inhibitors is the specificity of renin (Kleinert H. D., Cardiovasc. Drugs, 1995, 9, 645).
- the only substrate known for renin is angiotensinogen, which can only be processed (under physiological conditions) by renin.
- ACE can also cleave bradykinin besides Ang I and can be bypassed by chymase, a serine protease (Husain A., J. Hypertens., 1993, 11, 1155). In patients inhibition of ACE thus leads to bradykinin accumulation causing cough (5-20%)) and potentially life-threatening angioneurotic edema (0.1-0.2%)) (Konili Z. H.
- the present invention relates to novel compounds of the general formula I,
- lower alkylenedioxy refers to a lower alkylene substituted at each end by an oxygen atom.
- Examples of lower alkylenedioxy groups are preferably methylenedioxy and ethylenedioxy.
- sp3-hybridized refers to a carbom atom and means that this carbon atom forms four bonds to four substituents placed in a tetragonal fashion around this carbon atom.
- salts encompasses either salts with inorganic acids or organic acids like hydrochloric or hydrobromic acid, sulfuric acid, phosphoric acid, citric acid, formic acid, acetic acid, maleic acid, tartaric acid, benzoic acid, methanesulfonic acid, p-toluenesulfonic acid, and the like that are non toxic to living organisms or in case the compound of formula I is acidic in nature with an inorganic base like an alkali or earth alkali base, e.g. sodium hydroxide, potassium hydroxide, calcium hydroxide and the like.
- inorganic acids or organic acids like hydrochloric or hydrobromic acid, sulfuric acid, phosphoric acid, citric acid, formic acid, acetic acid, maleic acid, tartaric acid, benzoic acid, methanesulfonic acid, p-toluenesulfonic acid, and the like that are non toxic to living organisms or in case the compound of formula I is acidic in nature
- L represents H; -COR 3 "; -COOR 3 "; -CONR 2 "R 3 "; whereby R 2 " and R 3 " represent independently lower alkyl, lower cycloalkyl - lower alkyl, which lower alkyl and lower cycloalkyl - lower alkyl groups are unsubstituted or monosubstituted with halogen, cyano, hydroxy, -OCOCH 3 , -CONH 2 , -COOH, -NH 2 , with the proviso that a carbon atom is attached at the most to one heteroatom in case this carbon atom is sp3 -hybridized.
- the compounds of general formula I can be manufactured by the methods outlined below, by the methods described in the examples or by analogous methods.
- Suitable carrier materials for injections are, for example, water, alcohols, polyols, glycerols and vegetable oils.
- Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols.
- Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
- the bicyclononene L (0.11 g, 0.11 mmol) was dissolved in THF (3 mL) and AcOH (0.3 mL) and treated with zinc (0.14 g, 2.2 mmol). The suspension was stirred for 2 h and filtered through a Titan® HPLC filter. The filtrate was evaporated under reduced pressure and the residue was used in the next step without further purification.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP0304622 | 2003-05-02 | ||
PCT/EP2004/004372 WO2004096116A2 (en) | 2003-05-02 | 2004-04-26 | Diazabicyclononene derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1622564A2 true EP1622564A2 (en) | 2006-02-08 |
Family
ID=33395698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04729414A Withdrawn EP1622564A2 (en) | 2003-05-02 | 2004-04-26 | Diazabicyclononene derivatives |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1622564A2 (es) |
JP (1) | JP2006525259A (es) |
KR (1) | KR20060015573A (es) |
CN (1) | CN1780838A (es) |
AU (1) | AU2004233577A1 (es) |
BR (1) | BRPI0409882A (es) |
CA (1) | CA2521898A1 (es) |
MX (1) | MXPA05011711A (es) |
RU (1) | RU2005137571A (es) |
WO (1) | WO2004096116A2 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004283821A1 (en) * | 2003-10-13 | 2005-05-06 | Actelion Pharmaceuticals Ltd. | Diazabicyclononene derivatives and their use as renin inhibitors |
CN1930170A (zh) * | 2003-10-23 | 2007-03-14 | 埃科特莱茵药品有限公司 | 二氮杂二环壬烯及四氢吡啶衍生物用作肾素抑制剂 |
JP2007513107A (ja) * | 2003-12-05 | 2007-05-24 | アクテリオン ファマシューティカルズ リミテッド | ジアザビシクロノネンおよび新側鎖を有するテトラヒドロピリジン誘導体 |
WO2006021403A1 (en) * | 2004-08-25 | 2006-03-02 | Actelion Pharmaceuticals Ltd | Bicyclononene derivatives |
ATE462703T1 (de) | 2004-08-25 | 2010-04-15 | Actelion Pharmaceuticals Ltd | Bicyclononen-derivate als renin-inhibitoren |
WO2006058546A1 (en) * | 2004-12-01 | 2006-06-08 | Actelion Pharmaceuticals Ltd | Novel lactame derivatives as renin inhibitors |
WO2006063610A1 (en) * | 2004-12-17 | 2006-06-22 | Actelion Pharmaceuticals Ltd | Heteroaryl substituted diazabicyclononene derivatives |
GB0428526D0 (en) | 2004-12-30 | 2005-02-09 | Novartis Ag | Organic compounds |
ATE514697T1 (de) * | 2005-01-28 | 2011-07-15 | Actelion Pharmaceuticals Ltd | 7-ä4-ä2-(2,6-dichloro-4- methylphenoxy)ethoxyüphenylü-3,9- diazabicycloä3.3.1ünon-6-ene-6-carbonsäure- cyclopropyl-(2,3-dimethylbenzyl)amid als renin- hemmer für die behandlung von bluthochdruck |
WO2006131884A2 (en) * | 2005-06-07 | 2006-12-14 | Actelion Pharmaceuticals Ltd | Thiazole substituted diazabicyclononane or-nonene derivatives as renin inhibitors |
GB0514203D0 (en) | 2005-07-11 | 2005-08-17 | Novartis Ag | Organic compounds |
US8129411B2 (en) | 2005-12-30 | 2012-03-06 | Novartis Ag | Organic compounds |
US20100166839A1 (en) * | 2006-03-16 | 2010-07-01 | Nicox S.A | Non peptidic renin inhibitors nitroderivatives |
AU2008253519A1 (en) | 2007-05-24 | 2008-11-27 | Merck Frosst Canada Ltd | Novel case of renin inhibitors |
BRPI0813900A2 (pt) | 2007-06-25 | 2014-12-30 | Novartis Ag | Derivados de n5-(2-etoxietil)-n3-(2-piridinil)-3,5-piperidinodicarboxa mida para uso como inibidores de renina |
US8334308B2 (en) | 2007-08-20 | 2012-12-18 | Merck Sharp & Dohme Corp. | Renin inhibitors |
CA2722734C (en) | 2008-05-05 | 2013-11-05 | Merck Frosst Canada Ltd. | 3,4-substituted piperidine derivatives as renin inhibitors |
JPWO2013038936A1 (ja) * | 2011-09-13 | 2015-03-26 | タカラバイオ株式会社 | ペルオキシダーゼ反応の停止方法及び反応停止剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3509161A (en) * | 1967-07-10 | 1970-04-28 | Boehringer & Soehne Gmbh | 3-phenyl-granatene-(2)-derivatives |
WO1997009311A1 (de) * | 1995-09-07 | 1997-03-13 | F. Hoffmann-La Roche Ag | Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz |
AU2003233963B2 (en) * | 2002-04-29 | 2008-09-11 | Actelion Pharmaceuticals Ltd | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases |
BR0312000A (pt) * | 2002-06-27 | 2005-03-22 | Actelion Pharmaceuticals Ltd | Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, uso dos compostos |
-
2004
- 2004-04-26 KR KR1020057020788A patent/KR20060015573A/ko not_active Application Discontinuation
- 2004-04-26 RU RU2005137571/04A patent/RU2005137571A/ru not_active Application Discontinuation
- 2004-04-26 JP JP2006505261A patent/JP2006525259A/ja active Pending
- 2004-04-26 MX MXPA05011711A patent/MXPA05011711A/es not_active Application Discontinuation
- 2004-04-26 WO PCT/EP2004/004372 patent/WO2004096116A2/en active Application Filing
- 2004-04-26 AU AU2004233577A patent/AU2004233577A1/en not_active Abandoned
- 2004-04-26 CA CA002521898A patent/CA2521898A1/en not_active Abandoned
- 2004-04-26 CN CNA2004800116500A patent/CN1780838A/zh active Pending
- 2004-04-26 EP EP04729414A patent/EP1622564A2/en not_active Withdrawn
- 2004-04-26 BR BRPI0409882-0A patent/BRPI0409882A/pt not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO2004096116A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU2004233577A1 (en) | 2004-11-11 |
CA2521898A1 (en) | 2004-11-11 |
JP2006525259A (ja) | 2006-11-09 |
KR20060015573A (ko) | 2006-02-17 |
WO2004096116A3 (en) | 2005-03-24 |
BRPI0409882A (pt) | 2006-05-23 |
RU2005137571A (ru) | 2006-05-10 |
MXPA05011711A (es) | 2006-01-23 |
WO2004096116A2 (en) | 2004-11-11 |
CN1780838A (zh) | 2006-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004096116A2 (en) | Diazabicyclononene derivatives | |
US20060009497A1 (en) | Novel tetrahydropyridine derivatives as renin inhibitors | |
ZA200509663B (en) | Tropane derivatives and their use as ACE inhibitors | |
ZA200509667B (en) | Azabicyclononene derivatives | |
US20060258648A1 (en) | 9-Azabicyclo'3.3.1 inon-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors | |
US20060217371A1 (en) | Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors | |
AU2004295092A1 (en) | Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain | |
EP1620403B1 (en) | Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives | |
AU2004283821A1 (en) | Diazabicyclononene derivatives and their use as renin inhibitors | |
WO2005054243A1 (en) | Diazabicyclononene derivatives and their use as renin inhibitors | |
EP1680427A1 (en) | Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors | |
US20060223795A1 (en) | Novel diazabicyclononene derivatives | |
WO2006058546A1 (en) | Novel lactame derivatives as renin inhibitors | |
US20060235056A1 (en) | Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives | |
EP1622906A1 (en) | Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051202 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
R17P | Request for examination filed (corrected) |
Effective date: 20051202 |
|
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BUR, DANIEL Inventor name: BEZENCON, OLIVIER Inventor name: WELLER, THOMAS Inventor name: SIFFERLEN, THIERRY Inventor name: REMEN, LUBOS Inventor name: RICHARD-BILDSTEIN, SYLVIA Inventor name: FISCHLI, WALTER |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20081101 |